Candel Therapeutics develops viral immunotherapies that are injected into tumors to fight cancer. CADL reports earnings on Thu, Nov 12, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for CADL are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in CADL in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CADL is in one of them and how their past CADL trades turned out.
Candel Therapeutics is a clinical stage biopharmaceutical company based in Needham, Massachusetts. It develops viral immunotherapies for cancer, which are engineered viruses injected directly into tumors to stimulate the body's immune system against cancer. Its lead candidate, aglatimagene besadenovec, is being studied mainly for localized prostate cancer and for lung cancer. Its treatments are aimed at patients with a range of solid tumors.
